Contract awardedImmunoglobulin

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

  • NHS England
  • East Midlands
  • Open procedure
  • 1 July 2024 to 30 April 2027

National framework agreement for the supply of specialist blood disorder treatments, including Haemophilia A and B. The contract covers a wide range of pharmaceutical products distributed across all UK regions to support NHS clinical requirements.

Awarded value
Not published
Published
19 February 2024
Awarded
31 May 2024
Contract length
34 months
Ends 30 April 2027

What the contract covers

Goods procurement under a national framework agreement

Supply of pharmaceutical products for the treatment of blood disorders, including Haemophilia A and B, to NHS healthcare providers.

  • Supply of products for the treatment of Blood Disorders including Haemophilia A and B
LotEstimated valueSMEs
CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIIINot statedNot stated
CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing FractionNot statedNot stated
CM/PHS/22/5661/11 Factor IX - High Purity Factor IXNot statedNot stated
CM/PHS/22/5661/12 Factor XNot statedNot stated
CM/PHS/22/5661/13 Factor XIII - Plasma DerivedNot statedNot stated
CM/PHS/22/5661/14 Factor XIII - RecombinantNot statedNot stated
CM/PHS/22/5661/15 Von willebrands factor / Factor VIIINot statedNot stated
CM/PHS/22/5661/16 Von willebrands factor - Plasma DerivedNot statedNot stated
CM/PHS/22/5661/17 Von willebrands factor - RecombinantNot statedNot stated
CM/PHS/22/5661/18 Fibrinogen ConcentrateNot statedNot stated
CM/PHS/22/5661/19 Prothrombin Complex driedNot statedNot stated
CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIIINot statedNot stated
CM/PHS/22/5661/20 Protein C ConcentrateNot statedNot stated
CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)Not statedNot stated
CM/PHS/22/5661/22 Freeze Dried PlasmaNot statedNot stated
CM/PHS/22/5661/23 CaplacizumabNot statedNot stated
CM/PHS/22/5661/03 EmicizumabNot statedNot stated
CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)Not statedNot stated
CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)Not statedNot stated
CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)Not statedNot stated
CM/PHS/22/5661/07 rFIX - Standard Half LifeNot statedNot stated
CM/PHS/22/5661/08 Recombinant Factor VIINot statedNot stated
CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfaNot statedNot stated

Terms and requirements

Contract type
Goods procurement under a national framework agreement
Procedure
Open procedure
Initial term
34 months
Extensions
14 months
Longest it can run
48 months
Contract dates
1 July 2024 to 30 April 2027
Certifications asked for
None stated
Lots
23
Suitable for SMEs
Yes
Category
Supplies
CPV codes
33600000

Services in this contract

Lifecycle

  1. Published
  2. Contract awarded
  3. Contract starts
  4. Contract ends

The full record

Official notice
Locked
See the full contract record
The buyer

NHS England

Type
National NHS body
Contracts, 24 months
1,807
Recorded value
£6.7bn
Typical contract
£71k
Buys most
  • Clinical placements and practice education capacity (335)
  • Commissioned health and higher education (programme unspecified) (117)
  • Commissioned health and social work professional education (97)
Contact details
Name
Locked
Email
Locked
Address
Locked
See everything NHS England buys

Similar immunoglobulin contracts and prices

14 immunoglobulin contracts were awarded in the last 24 months. See who won them and what they went for, next to this one.

See who won them →